New Research Released on Hemispherx Biopharma $HEB

Posted by Laura Swartz

November 28, 2016 at 8:51 PM

An Executive Informational Overview (EIO) is now available on specialty pharmaceutical company, Hemispherx Biopharma, Inc. (HEB-NYSE). The EIO is a 60-page report detailing Hemispherx's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more. It is available for download below.

Hemispherx_EIO_Cover_Image.jpg Download  Report

Snapshot of Hemispherx

Hemispherx has invested over two decades of R&D into safe, effective ways to modulate and amplify the immune system, and is now poised to enter a confirmatory Phase III U.S. trial with an RNA macromolecule that could become the only FDA-approved therapy for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). This candidate, Ampligen®, was approved for CFS/ME in Argentina in August 2016 and is available to patients in Europe through an early access program (EAP). CFS/ME is a debilitating disease with no known treatment to date but very active patient advocacy groups.

Hemispherx also holds rights to an FDA-approved product for genital warts, Alferon N Injection®, which is believed to be the world’s only approved natural interferon (IFN). Hemispherx has refined Alferon’s manufacturing to drastically increase efficiencies and reduce costs, and now seeks FDA approval for the new production method before relaunching Alferon. Hemispherx is headquartered in Philadelphia with GMP manufacturing and research facilities in New Jersey.

5 Key Points of Hemispherx's Business

  • In addition to its development in CFS/ME, the Ampligen® technology has also shown utility as a broad-spectrum antiviral that could help seasonal flu vaccines work against highly pathogenic pandemic viruses. Ampligen® holds orphan drug designation for Ebola in Europe and is in Phase II trials as an immuno-oncology immune driver against colorectal and ovarian cancers.

  • Hemispherx holds 49 issued and 13 pending patents, which includes protections for Ampligen® through 2028.

  • During 2016, Hemispherx appointed new leadership, including CEO Tom Equels, who have been focused on aggressive execution of corporate goals, including working closely with regulatory communities to bring candidates to market.

  • Hemispherx seeks co-development partners to help accelerate commercialization of its pipeline. The Company already has several academic research collaborations in place as well as fill and finish contract manufacturers for Ampligen® and development agreements/licenses for Alferon in Latin America, the Middle East, and Australia/New Zealand.

  • Hemispherx reports that it holds cash and cash equivalents of approximately $8 million, following an equity financing of $4.5 million in net proceeds during August 2016. The Company aims to raise roughly $15 million to complete its manufacturing upgrade for Alferon. Hemispherx has also recently implemented austerity measures to reduce costs and expenses.

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on Hemispherx Biopharma, Inc.

*******************************************

Topics: HEB

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Topic